Osteoporosis News and Research

Latest Osteoporosis News and Research

$DMPA injectible contraceptive associated with increased risk of bone fracture$

DMPA injectible contraceptive associated with increased risk of bone fracture

A new study presented today at the World Congress on Osteoporosis (IOF WCO-ECCEO10) in Florence, Italy shows that DMPA, a commonly used injectible contraceptive, is associated with higher risk of bone fracture when used alone, and not in combination with estrogens.

7 May 2010

Study analyzes epidemiology of falls among elderly men

Falls and fall prevention are a major concern for the elderly and people with osteoporosis, a common chronic disease which causes weak and fragile bones. People with osteoporosis are at increased risk of fracture, even after a minor fall from standing height.

7 May 2010

IOF WCO-ECCEO10 osteoporosis congress opens in Florence, Italy

A record number of researchers and clinicians from some 100 countries gathered today in Florence, Italy to share new information about osteoporosis, a serious chronic disease which leads to weakened bones and fractures in as many as one in three women and one in five men over the age of fifty.

6 May 2010

RayBiotech announces biomarker grant winners

RayBiotech, Inc. has announced the winners of its Biomarker Discovery Pilot Grant program. In total, 18 award recipients were chosen for grants of up to $20,000 each, redeemable for RayBiotech products and services. "By offering these grants," states Dr. Ray (Ruopan) Huang, Founder and President of RayBiotech, "we intend to demonstrate that any researcher with a modest research budget can successfully discover and validate disease-related biomarkers using our antibody arrays."

6 May 2010

New York federal court jury favors Merck in Maley FOSAMAX case

Merck today said a unanimous federal court jury in New York found in its favor in the Maley v. Merck case, rejecting the claims of a plaintiff who blamed her dental and jaw-related problems on her FOSAMAX use.

6 May 2010

Watson Laboratories files raloxifene hydrochloride tablet ANDA

Watson Pharmaceuticals, Inc. today confirmed that its subsidiary, Watson Laboratories, Inc. filed an Abbreviated New Drug Application (ANDA) with the U.S. Food and Drug Administration (FDA) seeking approval to market a raloxifene hydrochloride tablet. Watson's raloxifene hydrochloride tablet is a generic version of Eli Lilly's EVISTA®.

6 May 2010

Study shows training in rhythmic gymnastics improves bone health in adolescent girls

According to a new study accepted for publication in The Endocrine Society's Journal of Clinical Endocrinology & Metabolism, long-term elite rhythmic gymnastics exerts positive effects on volumetric bone density and bone geometry in adolescent girls.

5 May 2010

Alvine Pharmaceuticals reports data of ALV003 in gastric simulation model at DDW 2010

Alvine Pharmaceuticals, Inc., today announced the reporting of scientific data on the performance of its lead compound, ALV003, in a gastric simulation model. The data were presented at the 2010 Digestive Disease Week (DDW) meeting held in New Orleans, Louisiana.

5 May 2010

$Seniors who consume high dietary protein are less likely to suffer hip fractures$

Seniors who consume high dietary protein are less likely to suffer hip fractures

Seniors who consume a higher level of dietary protein are less likely to suffer hip fractures than seniors whose daily dietary protein intake is less, according to a new study by the Institute for Aging Research of Hebrew SeniorLife in Boston, an affiliate of Harvard Medical School.

5 May 2010

AdvaCAL named official partner of National Osteoporosis Foundation

AdvaCAL® calcium supplements is proud to announce that it has been named as an official partner of the National Osteoporosis Foundation (NOF), the nations' leading voluntary health organization dedicated to osteoporosis and bone health. This designation is reserved for companies that provide financial support to NOF, with products judged to be consistent with the NOF mission.

5 May 2010

Roche announces Health Canada approval for ACTEMRA to treat RA

Roche today announced that Health Canada has approved ACTEMRA(TM) (tocilizumab) to treat patients with rheumatoid arthritis (RA), a chronic, progressive inflammatory disease of the joints and surrounding tissues that is associated with intense pain, irreversible joint destruction and systemic complications, such as fatigue and anemia.

4 May 2010

$Osteoporosis screening can reduce risk of future fractures$

Osteoporosis screening can reduce risk of future fractures

One in two women in the United States will have an osteoporosis-related fracture in her lifetime. However, according to a review article published in the May 2010 issue of the Journal of the American Academy of Orthopaedic Surgeons (JAAOS), only a few of these women will be tested and treated for osteoporosis, which if identified and treated, could dramatically decrease their risk of future fractures.

4 May 2010

Physical activity when young reduces risk of developing osteoporosis

The positive effects of exercise while growing up seem to last longer than previously believed. New findings suggest that physical activity when young increases bone density and size, which may mean a reduced risk of osteoporosis later in life, reveals a thesis from the Sahlgrenska Academy at the University of Gothenburg, Sweden.

4 May 2010

JGH researchers identify 13 new genes associated with osteoporosis, bone weakness

A team of international researchers has identified 20 genes associated with osteoporosis and bone weakness, including 13 genes never previously associated with the disease. Osteoporosis is a highly heritable trait, but this marks the largest international effort to conclusively identify genes linked to the often-devastating bone disorder.

4 May 2010

Pfizer to maintain top spot in prescription sales through mergers and acquisitions

The rheumatoid arthritis treatment Humira will replace Lipitor as the world's biggest-selling drug in 2016, but a familiar name, Pfizer, will still be the biggest seller of medicines after the patent cliff according to the World Preview 2016 report published today by EvaluatePharma, the premier provider of pharma and biotech analysis.

3 May 2010

VIMOVO delayed-release tablets receive FDA approval

AstraZeneca and POZEN Inc. today announced the U.S. Food and Drug Administration has approved VIMOVO (naproxen and esomeprazole magnesium) delayed-release tablets for the relief of signs and symptoms of osteoarthritis, rheumatoid arthritis, and ankylosing spondylitis, and to decrease the risk of developing gastric ulcers in patients at risk of developing NSAID-associated gastric ulcers.

3 May 2010

PAF annual report offers summary of issues impacting Americans' access to healthcare

Patient Advocate Foundation -- a national non-profit organization that seeks to safeguard patients through effective mediation assuring access to care, maintenance of employment and preservation of their financial stability relative to their diagnosis of life threatening or debilitating diseases -- today released their annual Patient Data Analysis Report, which documents the scope and complexity of the healthcare finance, access and job retention issues routinely confronted by patients at the national and state-specific level.

29 Apr 2010

New theory on muscle and bone diseases

Traditionally, doctors and clinicians thought diseases that affect muscles or bones affected those areas specifically. For example, bone diseases only affect bones, or muscle diseases only concerned muscles. But recent evidence supports the notion that bones and muscles are more interconnected than previously thought.

29 Apr 2010

DFine granted US patent relating to StabiliT Vertebral Augmentation System

DFine, Inc., a developer of minimally invasive solutions for treating vertebral compression fractures, announced today that the United States Patent & Trademark Office has issued Patent 7,678,116 relating to the StabiliT® Vertebral Augmentation System. Two additional Notices of Allowance have also been issued with patents expected later this year.

29 Apr 2010

Research reveals therapeutic benefit of ACTH in treatment of osteonecrosis

Researchers at Mount Sinai School of Medicine have found a potential new treatment for osteonecrosis, or the death of bone tissue, in people who are treated with steroids for several common medical conditions. There are currently no treatment options for people with this debilitating disease. The research is published in the April 27 issue of Proceedings of the National Academy of Sciences.

28 Apr 2010